Zeba M Khan
Overview
Explore the profile of Zeba M Khan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
550
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rana B, Jimenez H, Khan Z, Narayanan N
J Community Health
. 2024 Jul;
49(5):829-834.
PMID: 39014152
Backgroud: Socioeconomic status (SES) plays a vital role in determining vaccination uptake and attitudes. Vaccine hesitancy varies among different communities, yet knowledge of vaccine attitudes among Asian-Americans is limited. Objective:...
2.
Levy P, Lemanski T, Crossan C, Lefebvre A, Briere J, Degli Esposti L, et al.
Expert Rev Pharmacoecon Outcomes Res
. 2024 Jun;
24(8):967-975.
PMID: 38848115
Objective: To evaluate the cost-effectiveness of a single-pill combination (SPC) of perindopril/amlodipine/indapamide versus its free equivalent combination (FEC) in adults with hypertension in Italy. Methods: A Markov model was developed...
3.
Kengne A, Briere J, Gudina I, Jiang X, Kodjamanova P, Bennetts L, et al.
Expert Rev Pharmacoecon Outcomes Res
. 2024 Feb;
24(7):807-816.
PMID: 38366854
Introduction: Suboptimal medication adherence is common among patients with cardiovascular diseases. We sought evidence on non-pharmacological interventions used to support adherence for patients with hypertension and/or dyslipidemia. Methods: We searched...
4.
Kengne A, Briere J, Le Nouveau P, Kodjamanova P, Atanasov P, Kochoedo M, et al.
Expert Rev Pharmacoecon Outcomes Res
. 2023 Dec;
24(7):817-827.
PMID: 38088763
Objectives: Hypertension is a leading cause of death and disease burden followed by dyslipidemia. Their asymptomatic nature leads to low adherence and persistence to treatments. A systematic literature review (SLR)...
5.
Kengne A, Briere J, Zhu L, Li J, Bhatia M, Atanasov P, et al.
Expert Rev Pharmacoecon Outcomes Res
. 2023 Oct;
24(1):143-154.
PMID: 37862440
Introduction: We aimed to summarize evidence on the effect of poor medication adherence on clinical outcomes and health resource utilization (HRU) among patients with hypertension and/or dyslipidemia. Areas Covered: A...
6.
Khan Z, Briere J, Olewinska E, Khrouf F, Nikodem M
J Mark Access Health Policy
. 2023 Oct;
11(1):2262073.
PMID: 37808119
Heart failure is a chronic disease linked with significant morbidity and mortality, and uncontrolled resting heart rate is a risk factor for adverse outcomes. This systematic literature review aimed to...
7.
Parker L, Shaul A, Murphy B, Khan Z
J Health Econ Outcomes Res
. 2023 Sep;
3(1):107-121.
PMID: 37662657
Certain governmental agencies, patient advocacy organizations, and pharmaceutical manufacturers have implemented programs to assist patients in overcoming barriers to accessing healthcare. Recently, such programs have expanded their services, helping both...
8.
Pastakia S, Tran D, Manji I, Schellhase E, Karwa R, Miller M, et al.
Res Social Adm Pharm
. 2020 Aug;
16(11):1519-1525.
PMID: 32792324
Background: The field of global health has grown with multiple different public and private stakeholders engaging in the effort to improve health outcomes for underserved populations around the world. There...
9.
Seabury S, Goldman D, Gupta C, Khan Z, Chandra A, Philipson T, et al.
Forum Health Econ Policy
. 2019 Aug;
19(1):141-156.
PMID: 31419891
Introduction: There have been significant improvements in both treatment and screening efforts for many types of cancer over the past decade. However, the effect of these advancements on the survival...
10.
Chandra A, MacEwan J, Campinha-Bacote A, Khan Z
Forum Health Econ Policy
. 2019 Aug;
19(1):71-86.
PMID: 31419890
Background: Since the start of the War on Cancer there have been enormous investments in improving oncology treatment. The return to society generated by this investment is unknown. We estimate...